Acerca de este artículo
Article Category: In My View
Publicado en línea: 21 abr 2018
Páginas: 35 - 37
DOI: https://doi.org/10.17225/jhp.00023
© 2018
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Octapharma's core business is the development and production of human proteins from human plasma and cell lines. As the company moves into the recombinant arena, Chairman Wolfgang Marguerre discusses opportunities and threats with Editor-in-Chief Kate Khair